Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability Study of Rivastigmine Transdermal Patch vs Exelon® Patch
NCT03573050Phase 1Completed
- Sponsor
- SocraTec R&D
- Start
- May 2018
- Primary completion
- Jul 2018
- Modality
- Reversible Covalent Inhibitors, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of rivastigmine in Alzheimer's disease (AD) (2 arms), sponsored by SocraTec R&D. Primary endpoints: Area Under the Curve at Steady State, Trough Concentration at Steady State and 1 more. Started May 2018; status: completed.
02
Drugs
rivastigmine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03573050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03573050.